Status:
RECRUITING
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Lead Sponsor:
University of Bologna
Collaborating Sponsors:
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Conditions:
Cancer Related Cardiovascular Toxicity
Eligibility:
All Genders
18+ years
Brief Summary
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction,...
Eligibility Criteria
Inclusion
- Age 18 years old or older
- Capable of giving informed consent
- Diagnosis of cancer scheduled for treatment according to treating physician's discretion
- Life expectancy \>1 year
- For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
Exclusion
- Age \<18 years old
- Not able to give informed consent
- Life expectancy \<1 year
- Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Key Trial Info
Start Date :
May 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT06086132
Start Date
May 1 2025
End Date
December 31 2026
Last Update
June 19 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Bologna
Bologna, Italy
2
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
Palermo, Italy
3
Ss. Cyril and Methodius University in Skopje, University Clinic
Skopje, North Macedonia
4
University of Belgrade, Clinical Center of Serbia
Belgrade, Serbia